For the quarter ending 2025-09-30, NRXPW made $242K in revenue. -$5,890K in net income. Net profit margin of -2433.88%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Net patient service revenue | 242 | - | ||
| Cost of patient services | 97 | - | ||
| Research and development | 1,429 | 987 | ||
| Selling, general and administrative | 2,808 | - | ||
| Depreciation and amortization expense | 26 | - | ||
| Settlement (income) expense | -94 | 0 | ||
| General and administrative | - | 2,743 | ||
| Total operating expenses | 4,266 | 3,730 | ||
| Loss from operations | -4,024 | -3,730 | ||
| Interest income | 2 | 2 | ||
| Interest expense | 0 | 0 | ||
| Change in fair value of convertible notes payable | 1,502 | 5,565 | ||
| Change in fair value of warrant liabilities | 4,963 | 6,414 | ||
| Loss on issuance of registered direct offering | 0 | 0 | ||
| Loss on consideration shares and warrants | 0 | 0 | ||
| Convertible note default penalty | 0 | 0 | ||
| Loss on convertible note conversions | -772 | -1,874 | ||
| Gain on exercise of warrant liabilities | 5,369 | - | ||
| Total other expense (income) | -1,866 | -13,851 | ||
| Net loss | -5,890 | -17,581 | ||
| Change in fair value of convertible note attributed to credit risk | 0 | - | ||
| Other comprehensive loss | 0 | - | ||
| Comprehensive loss | -5,890 | - | ||
| Basic and diluted (in dollars per share) | -0.27 | -0.98 | ||
| Basic and diluted (in shares) | 22,231,178 | 17,934,196 | ||
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)